Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 831

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 831
---
 with accompanying qualitative disclosures. The amendments in ASU 2023-09are effective fiscal years beginning after December 31, 2024, and early adoption is permitted. The Company does not believe that the adoption of ASU 2023-09will have a material impact on its consolidated financial statements. Grant Income- In April 2021, the Company received approval from the Department of Health and Human Services for a $ 400,000grant. The grant was to conduct research for a low-costtopical immunotherapy formulation suitable for treating cervical cancer in low and middle-income countries and low resource settings in the U.S. Additionally, the Company assumed in the reverse merger a $ 2,000,000Business Innovation Research grant, a two year grant that was initiated in June 2023 and set to expire in June 2025, to support the clinical development of REM-001for the treatment of CMBC and had a remaining balance of $ 900,000as of the merger date. For the years ended December 31, 2024 and 2023, the Company recognized $ 58,000and $ 42,000of grant income in the consolidated statements of operations. F-77

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

Research and Development Expenses- Research and development consists of expenses incurred in connection with the discovery and development of product candidates. The Company expenses research and development costs as incurred.

Acquired In-ProcessResearch and Development -Acquired in-processresearch and development expenses consist of existing research and development projects at the time of the acquisition. Projects that qualify as IPR&D assets represent those that have not yet reached technological feasibility and had no alternative future use, which resulted in a write-offof these IPR&D assets to acquired in-processresearch and development expenses in our consolidated statements of operations.

Concentration of Credit Risk- The Company maintains cash balances in domestic financial institutions. These balances are insured by the Federal Deposit Insurance Corporation up to $ 250,000. As of December 31, 2024, the uninsured portion of cash held by the Company was approximately $ 11,727,000.

Fair Value of Financial Instruments- ASC 820, Fair Value Measurement, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable